# TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)

> **NCT05525455** · PHASE1,PHASE2 · TERMINATED · sponsor: **Teon Therapeutics, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Advanced Cancer
- Advanced Solid Tumor
- Cancer
- Oncology

## Interventions

- **DRUG:** TT-816
- **DRUG:** A PD-1 inhibitor

## Key facts

- **NCT ID:** NCT05525455
- **Lead sponsor:** Teon Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-29
- **Primary completion:** 2023-09-07
- **Final completion:** 2023-09-07
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Company operational decision. Decision to stop study is not due to safety or efficacy concerns.
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525455, "TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05525455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*